At a glance
ClinicalIndex Comparison RecordN/ACompleted· 46 enrolled
Drug / intervention
AC5 Topical Hemostatic Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions
In Brief
A clinical study evaluating AC5 Topical Hemostatic Device for Skin Neoplasms. Completed, enrolled 46 participants across 1 site.
Detailed Summary
This study is designed to monitor patient safety after excision of skin lesions and subsequent application of AC5 topical hemostatic agent and to assess the performance of AC5 for controlling bleeding in skin wounds.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Neoplasms
CountriesIreland
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedMar 2016
Primary CompletionJun 2016
TodayJul 2026
First PostedMar 9, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.3 years ago
Interventions
AC5 Topical Hemostatic Devicedevice
Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient